|
| 37387213 | TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. | Future Oncol | 2024 |
| 36394849 | Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. | JAMA Oncol | 2023 |
| 37633306 | Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. | Lancet | 2023 |
| 37657462 | Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. | Lancet Oncol | 2023 |
| 37673211 | Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. | Ann Oncol | 2023 |
| 37318638 | Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells. | Breast Cancer Res Treat | 2023 |
| 37076495 | Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer. | NPJ Breast Cancer | 2023 |
| 37275963 | Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclibâ¿¿+â¿¿endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2- early breast cancer. | Ther Adv Med Oncol | 2023 |
| 37141550 | A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. | JCO Precis Oncol | 2023 |
| 37141549 | Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. | JCO Precis Oncol | 2023 |
| 37103597 | Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study). | Breast Cancer Res Treat | 2023 |
| 37438196 | Circulating Tumor DNA in Breast Cancer: Current and Future Applications. | Clin Breast Cancer | 2023 |
| 37269905 | ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. | Ann Oncol | 2023 |
| 37133651 | HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. | Target Oncol | 2023 |
| 37477704 | Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. | Clin Cancer Res | 2023 |
| 37265453 | Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer. | Clin Cancer Res | 2023 |
| 37261814 | An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer. | Clin Cancer Res | 2023 |
| 36920760 | Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia. | N Engl J Med | 2023 |
| 36401732 | The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HRâ¿¿+â¿¿/HER2â¿¿-) advanced/metastatic breast cancer. | Breast Cancer Res Treat | 2023 |
| 36743521 | TRK inhibitor in a patient with metastatic triple-negative breast cancer and <i>NTRK</i> fusions identified <i>via</i> cell-free DNA analysis. | Ther Adv Med Oncol | 2023 |
| 36435607 | Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer. | Hematol Oncol Clin North Am | 2023 |
| 36643653 | Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. | Ther Adv Med Oncol | 2023 |
| 36608309 | Reply to G.-F. Li et al, K. Altundag, and N. SG et al. | J Clin Oncol | 2023 |
| 36831621 | Mechanisms of Resistance to Antibody-Drug Conjugates. | Cancers (Basel) | 2023 |
| 36772966 | Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. | Oncologist | 2023 |
| 36493359 | Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. | Oncologist | 2023 |
| 36861085 | Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. | Ther Adv Med Oncol | 2023 |
| 36379186 | Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. | Eur J Cancer | 2023 |
| 34795441 | Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. | Nat Nanotechnol | 2022 |
| 35680967 | Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. | NPJ Breast Cancer | 2022 |
| 35584336 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. | J Clin Oncol | 2022 |
| 35583555 | VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results. | Clin Cancer Res | 2022 |
| 35840573 | AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. | Nat Commun | 2022 |
| 35545724 | Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. | Breast Cancer Res Treat | 2022 |
| 35642907 | Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan. | Oncologist | 2022 |
| 35700410 | Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. | JCO Precis Oncol | 2022 |
| 35852437 | Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. | Oncologist | 2022 |
| 36107417 | An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low). | JAMA Oncol | 2022 |
| 36067449 | Reply to R. Nishihara et al. | J Clin Oncol | 2022 |
| 36038616 | Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. | NPJ Breast Cancer | 2022 |
| 36333333 | Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer. | NPJ Breast Cancer | 2022 |
| 36332363 | Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer. | EBioMedicine | 2022 |
| 35962750 | Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization. | Oncologist | 2022 |
| 36383904 | Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2. | Cancer J | 2022 |
| 36198984 | Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). | Breast Cancer Res Treat | 2022 |
| 35923930 | Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. | Ther Adv Med Oncol | 2022 |
| 36027558 | Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. | J Clin Oncol | 2022 |
| 36051470 | Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer. | Ther Adv Med Oncol | 2022 |
| 35309087 | AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. | Ther Adv Med Oncol | 2022 |
| 34965945 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. | Clin Cancer Res | 2022 |